WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC

Overview of new ATC codes decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codes will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code 1) Implementation in the ATC/DDD index
A03AX15menthae piperitae aetheroleum01.09.20202021
A05BA09metadoxine01.09.20202021
A06AX08tenapanor01.09.20202021
A10BD26metformin and lobeglitazoneFinal2021
A10BG04lobeglitazoneFinal2021
A10BH08teneligliptinFinal2021
A10BJ07beinaglutide01.09.20202021
A10BK07luseogliflozinFinal2021
A16AX16givosiranFinal2021
A16AX17triheptanoin01.09.20202021
A16AX18lumasiran01.09.20202021
A16AX30sodium benzoate and sodium phenylacetateFinal2021
B03AD05ferrous gluconateFinal2021
B05XA18zinc sulfateFinal2021
B06AX02betibeglogene autotemcelFinal2021
C01DX22vericiguat01.09.20202021
C09BX05ramipril and bisoprololFinal2021
C10AX16inclisiranFinal2021
C10BA10bempedoic acid and ezetimibe 2)01.09.20202021
C10BX18atorvastatin, amlodipine and ramiprilFinal2021
D01BA03fosravuconazole01.09.20202021
D05AX55tazarotene and ulobetasol01.09.20202021
D06BX03tirbanibulin01.09.20202021
D10AF07minocycline01.09.20202021
D11AH07tralokinumab01.09.20202021
D11AX26caffeineFinal2021
G02CX05bremelanotideFinal2021
G03AA18drospirenone and estetrol01.09.20202021
H01AC07somapacitanFinal2021
H01CC54relugolix, estradiol and norethisterone01.09.20202021
H02CA03ketoconazole 3)Final2021
H05AA04abaloparatideFinal2021
H05BX05calcifediol 4)Final2021
J01DH56imipenem, cilastatin and relebactamFinal2021
J01DI04cefiderocolFinal2021
J01MA24levonadifloxacinFinal2021
J01MA25lascufloxacin01.09.20202021
J04AK08pretomanid01.09.20202021
J05AJ04cabotegravir 5)01.09.20202021
J05AX28bulevirtideFinal2021
J05AX29fostemsavirFinal2021
J07BB04influenza, virus like particles 01.09.20202021
J07BX02ebola vaccines01.09.20202021
L01EE04selumetinib01.09.20202021
L01EH03tucatinib01.09.20202021
L01EL03zanubrutinib01.09.20202021
L01EM04duvelisib01.09.20202021
L01EX15pexidartinib01.09.20202021
L01EX16erdafitinib01.09.20202021
L01EX17capmatinib01.09.20202021
L01EX18avapritinib01.09.20202021
L01EX19ripretinib01.09.20202021
L01EX20pemigatinib01.09.20202021
L01EX21tepotinib01.09.20202021
L01XC34moxetumomab pasudotoxFinal2021
L01XC35tafasitamabFinal2021
L01XC36enfortumab vedotinFinal2021
L01XC37polatuzumab vedotinFinal2021
L01XC38isatuximabFinal2021
L01XC39belantamab mafodotinFinal2021
L01XC40dostarlimabFinal2021
L01XC41trastuzumab deruxtecan01.09.20202021
L01XK05veliparib01.09.20202021
L01XX69lurbinectedin01.09.20202021
L01XX70axicabtagene ciloleucelFinal2021
L01XX71tisagenlecleucelFinal2021
L01XY02pertuzumab and trastuzumab01.09.20202021
L04AA45filgotinibFinal2021
L04AA46itacitinibFinal2021
L04AA47inebilizumab01.09.20202021
L04AC19satralizumabFinal2021
M02AA29esflurbiprofenFinal2021
M09AX08golodirsenFinal2021
M09AX09onasemnogene abeparvovecFinal2021
M09AX10risdiplamFinal2021
M09AX11palovarotene01.09.20202021
N01BB59bupivacaine and meloxicamFinal2021
N02AA11oxymorphone01.09.20202021
N02BG11mirogabalinFinal2021
N03AX25cenobamate01.09.20202021
N03AX26fenfluramine01.09.20202021
N04CX01istradefyllineFinal2021
N05CD15nimetazepamFinal2021
R01AD59mometasone, combinations01.09.20202021
R07AX32ivacaftor, tezacaftor and elexacaftorFinal2021
S01GA07brimonidineFinal2021
S01LA07abicipar pegolFinal2021
1) Final: indicates that the date for objection has expired
2) Alteration of ATC 4th level name to C10BA Combinations of various lipid modifying agents
3) Oral formulations only indicated in treatment of Cushing’s syndrome
4) Oral formulations only indicated in treatment of renal secondary hyperparathyroidism
5) New ATC 4th level J05AJ Integrase inhibitors valid from January 2021

New ATC level codes (other than 5th levels)

ATC codeATC level nameDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
N04COther antiparkinson drugsFinal2021
N04CXOther antiparkinson drugsFinal2021
J05AJ Integrase inhibitors 01.09.20202021
L01CETopoisomerase 1 inhibitors01.09.20202021
L01EProtein kinase inhibitors01.09.20202021
L01EABCR-ABL tyrosine kinase inhibitors01.09.20202021
L01EBEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors01.09.20202021
L01ECB-Raf serine-threonine kinase (BRAF) inhibitors01.09.20202021
L01EDAnaplastic lymphoma kinase (ALK) inhibitors01.09.20202021
L01EEMitogen-activated protein kinase (MEK) inhibitors01.09.20202021
L01EFCyclin-dependent kinases (CDK) inhibitors01.09.20202021
L01EGMammalian target of rapamycin (mTOR) kinase inhibitors01.09.20202021
L01EHHuman epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors01.09.20202021
L01EJJanus Associated Kinase (JAK) inhibitors01.09.20202021
L01EKVascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors01.09.20202021
L01ELBruton`s tyrosine kinase (BTK) inhibitors01.09.20202021
L01EMPhosphatidylinositol-3-kinase (Pi3K) inhibitors01.09.20202021
L01EXOther protein kinase inhibitors01.09.20202021
L01XFRetinoids for cancer treatment01.09.20202021
L01XGProteasome inhibitors01.09.20202021
L01XHHistone deacetylase (HDAC) inhibitors01.09.20202021
L01XJHedgehog pathway inhibitors01.09.20202021
L01XKPoly (ADP-ribose) polymerase (PARP) inhibitors01.09.20202021
1) Final: indicates that the date for objection has expired

Last updated: 2020-05-07